Literature DB >> 22865879

The liberation of CD44 intracellular domain modulates adenoviral vector transgene expression.

Cristhian J Ildefonso1, Wesley S Bond, Azza R Al-Tawashi, Mary Y Hurwitz, Richard L Hurwitz.   

Abstract

The success of gene therapy in the ocular environment is partly due to the presence of hyaluronan in vitreous. Here we explore the mechanism of hyaluronan-mediated enhancement of adenoviral vector transgene expression. Introduction of hyaluronan receptor CD44 into CD44-negative cells followed by transduction in the presence of vitreous with an adenoviral vector containing an IL-12-coding transgene increases IL-12 secretion. We demonstrate that sequential CD44 proteolysis is responsible for hyaluronan-mediated enhancement. Metalloproteinase or γ-secretase inhibitors decrease adenoviral-mediated transgene expression. Deletion of these proteolytic sites in CD44 also inhibits transgene expression. Expression of CD44 with a mutation to prevent phosphorylation of serine 325 inhibits the response to vitreous. Expression of the CD44 intracellular domain enhances transgene expression in the absence of vitreous. CD44-mediated enhancement of gene expression was observed with vectors using different promoters and appears because of an increase in mRNA production, not because of an increase in vector transduction as determined by quantitative RT-PCR and quantitative PCR, respectively. These data fit a model where the interaction of hyaluronan in vitreous and CD44 modulates transgene expression by initiating CD44 proteolysis and release of the cytoplasmic domain, resulting in increased transgene transcription.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865879      PMCID: PMC3463356          DOI: 10.1074/jbc.M112.347369

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Immune response following intraocular delivery of recombinant viral vectors.

Authors:  J Bennett
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

Review 2.  Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling.

Authors:  Mark E Fortini
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

3.  Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.

Authors:  Karl E Miletti-González; Kyle Murphy; Muthu N Kumaran; Abhilash K Ravindranath; Roman P Wernyj; Swayamjot Kaur; Gregory D Miles; Elaine Lim; Rigel Chan; Marina Chekmareva; Debra S Heller; David Foran; Wenjin Chen; Michael Reiss; Elisa V Bandera; Kathleen Scotto; Lorna Rodríguez-Rodríguez
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

4.  Modulation of adenoviral transduction in vitro and in vivo by hyaluronan and its receptor CD44.

Authors:  Saumya R Chaudhuri; Joshua N Mallam; Patricia Chévez-Barrios; Lalita Wadhwa; Philip Ng; Mary Y Hurwitz; Richard L Hurwitz
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

Review 5.  CD44 in inflammation and metastasis.

Authors:  J Lesley; R Hyman; N English; J B Catterall; G A Turner
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

6.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.

Authors:  Peter A Campochiaro; Quan Dong Nguyen; Syed Mahmood Shah; Michael L Klein; Eric Holz; Robert N Frank; David A Saperstein; Anurag Gupta; J Timothy Stout; Jennifer Macko; Robert DiBartolomeo; Lisa L Wei
Journal:  Hum Gene Ther       Date:  2006-02       Impact factor: 5.695

7.  Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma.

Authors:  Cristhian J Ildefonso; Lingkun Kong; Ann Leen; Samantha J Chai; Veronica Petrochelli; Murali Chintagumpala; Mary Y Hurwitz; Patricia Chévez-Barrios; Richard L Hurwitz
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

8.  Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

Authors:  Bruno Sangro; Guillermo Mazzolini; Juan Ruiz; Maite Herraiz; Jorge Quiroga; Ignacio Herrero; Alberto Benito; Javier Larrache; Jesus Pueyo; Jose Carlos Subtil; Cristina Olagüe; Josu Sola; Belén Sádaba; Carlos Lacasa; Ignacio Melero; Cheng Qian; Jesus Prieto
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

9.  CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells.

Authors:  L Y Bourguignon; Z Gunja-Smith; N Iida; H B Zhu; L J Young; W J Muller; R D Cardiff
Journal:  J Cell Physiol       Date:  1998-07       Impact factor: 6.384

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  2 in total

1.  Versican G1 domain enhances adenoviral-mediated transgene expression and can be modulated by inhibitors of the Janus kinase (JAK)/STAT and Src family kinase pathways.

Authors:  Patricia Y Akinfenwa; Wesley S Bond; Cristhian J Ildefonso; Mary Y Hurwitz; Richard L Hurwitz
Journal:  J Biol Chem       Date:  2017-07-06       Impact factor: 5.157

2.  sCD44 overexpression increases intraocular pressure and aqueous outflow resistance.

Authors:  Michael Giovingo; Michael Nolan; Ryan McCarty; Iok-Hou Pang; Abbot F Clark; Rachel M Beverley; Steven Schwartz; W Daniel Stamer; Loyal Walker; Algis Grybauskas; Kevin Skuran; Paulius V Kuprys; Beatrice Y J T Yue; Paul A Knepper
Journal:  Mol Vis       Date:  2013-11-01       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.